Cellular phone manufacturers and service providers who fear that the U.S. International Trade Commission will ban the importation of phones containing Qualcomm Inc. chips will once again have to wait for a ruling on the matter.
Two prominent Democratic lawmakers on Thursday charged the U.S. Food and Drug Administration with stonewalling repeated requests for reports on food and medicine safety, threatening to issue subpoenas if the asked-for documents are not presented by June 1, they said.
Two patent infringement suits have been added to the consolidated antitrust class action lawsuit filed over alleged inequitable conduct during the patent application process for the blockbuster painkiller OxyContin.
The judge overseeing the multidistrict products liability litigation over AstraZeneca’s bipolar medication Seroquel has denied a motion to compel the drug maker to provide eight files of key electronic and hard copy data.
More than a dozen cases in the multidistrict litigation over Pfizer Inc.’s anti-inflammatory pain medications Bextra and Celebrex have recently been tossed by the federal judge overseeing the case.
Drug maker Ivax Corp. has asked a federal judge to force Depomed Inc. to disclose documents that Ivax believes are crucial to its counterclaim in their patent litigation.
The U.S. Supreme Court should not use the Tamoxifen Citrate antitrust lawsuits as an opportunity to weigh in on the issue of authorized generics, even though the appeals court that decided the case mistakenly relied on an overly stringent standard, the Solicitor General’s Office said Wednesday.
International trade experts predict that the U.S. International Trade Commission will issue an order banning the importation of several cell phones containing Qualcomm chips, a decision that manufacturers say will cripple their businesses.
The U.S. Food and Drug Administration suffers from staffing shortages, drawn out reviews, backlogs of applications and a lack of resources, according to a survey of the top pharmaceutical, biotechnology and life sciences companies.
More than 500 product liability suits involving Ortho-McNeil Pharmaceutical Co.’s popular birth-control patch Ortho Evra have been consolidated in a Cleveland federal court, according to court documents.
Fresenius Medical Care has lashed out at Baxter International Inc. for arguing against Fresenius’ bid to stay a second damages trial in a longstanding legal feud involving patents related to hemodialysis machines.
Drug companies Altana Pharma AG and Sun Pharmaceutical Industries Ltd. traded barbs on Monday over whether Altana could assert an exceptional case claim in an ongoing battle over Protonix’s ulcer treatment patent.
One of the most contentious and groundbreaking decisions in the last 20 years, the Supreme Court's ruling on the definition of obviousness has opened the floodgates to challenging all hosts of technology patents—and its timing couldn't be better for the open source community.
After encountering a roadblock in its long-running patent feud with Novartis AG, Teva Pharmaceutical Industries Ltd. said late Monday that a federal district court had vacated a temporary restraining order it had issued on Saturday that barred the Israeli generics maker from shipping a generic version of the drug.
Diagnostic company AmeriPath Inc. filed counterclaims Friday in a patent infringement suit brought by Luxembourg-based biotech company Advanced Biological Laboratories SA over HIV treatment patents.
The U.S. Food and Drug Administration has issued a safety warning on Avandia, concerned that the popular diabetes drug significantly boosts the risk of heart attack and heart-related deaths.
Sticking a price tag on a life sciences or biotechnology company’s intellectual property can be a tall order, but the challenge becomes even greater when that company files for bankruptcy protection.
An appeals court refused Monday to rehear Pfizer Inc.’s case against Apotex Inc., giving the Canadian generics-maker the green light to launch a generic form of Pfizer’s blockbuster blood-pressure drug Norvasc.
Immucor has agreed to shell out $2.5 million to settle a securities class-action suit brought by stockholders against the medical equipment manufacturer, accused of lying about its involvement in a 2004 Milan hospital scandal.
Generic drug company Zydus Pharmaceuticals USA Inc. has shot back at drug maker Three Rivers Pharmaceuticals LLC, asserting that its ribavirin caplets and tablets do not infringe Three Rivers’ patent for its hepatitis C drug.